Ubrogepant

Overactive Bladder

The Cleveland ClinicSmall moleculeUnknownActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 89/ 100

Competitive context

13 Active assets in the Overactive Bladder cohort.

Asset / Sponsor	Phase	Rating
Mirabegron VA Office of Research and Development	Phase 4	BB
Trospium Allergan	Phase 4	BB
Nabiximols Jazz Pharmaceuticals	Phase 3	BB
Solifenacin VA Office of Research and Development	Phase 4	B
Oxybutynin University of California, Davis	Phase 3	B

View all 21 →

Same molecule, other indications

Ubrogepant is also rated in:

migraine disorderActive

BBB

Indicative · Phase 4

79 / 100

migraine without auraActive

BB

Indicative · Phase 4

65 / 100

migraine with auraActive

B

Indicative · Phase 4

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.